What is the main purpose of this 10-Q filing?

The main purpose of this 10-Q filing is for Eli Lilly and Company to provide its investors and the public with a consolidated unaudited interim financial report for the fiscal quarter ended June 29, 1996, detailing its financial performance and operational activities during that period.

Where can I find the actual financial results and management discussion in this filing?

The provided text is a directory listing of the SEC filing, not the full report itself. To find the detailed financial results, management's discussion and analysis, and other substantive information, you would need to access the full 10-Q document, typically available through the SEC's EDGAR database or the company's investor relations website.

What key information should an investor look for in the complete 10-Q report?

Investors should look for critical financial data such as revenue and net income trends, analysis of sales performance for key products (e.g., Prozac, Cialis, etc.), updates on the research and development pipeline (including clinical trial progress and new drug approvals), significant changes in debt or equity, and any management commentary on future outlook, risks, and strategic initiatives.

Does this filing indicate any major positive or negative news for Eli Lilly?

The provided directory listing does not contain the content of the report, so it is not possible to determine from this snippet alone whether there is major positive or negative news. The full 10-Q report would be necessary to assess the company's performance and any significant developments during the quarter.

LLY 10-Q Quarterly Report Q2 FY1996 — Revenue, Net Income, EPS

Summary

Eli Lilly and Company's 10-Q filing for the period ending June 29, 1996, reveals a company focused on its pharmaceutical operations. While specific financial performance figures and detailed operational updates are not directly provided in the provided text snippet (which is a directory listing of the filing, not the report content itself), the filing indicates the company is adhering to its reporting obligations. Investors should look for the full report to understand the company's revenue, profitability, product pipeline, and any significant developments in its research and development efforts during the quarter. The filing's existence suggests a period of continued operation and compliance with SEC regulations. Key areas to scrutinize in the full report would include sales performance of key drugs, updates on clinical trials, and any strategic announcements regarding acquisitions, divestitures, or new market entries that could impact future growth and shareholder value.

Key Highlights

1Eli Lilly and Company (LLY) filed its 10-Q quarterly report for the period ending June 29, 1996.
2The filing was made on August 11, 1996, indicating timely compliance with SEC reporting requirements.
3The provided text is a directory listing of the SEC filing, not the full report content.
4Investors will need to access the full report to find detailed financial performance, operational results, and strategic updates.
5Key areas for investors to focus on in the complete filing include revenue, profitability, R&D pipeline, and sales of major pharmaceutical products.
6The filing signifies ongoing business operations and adherence to regulatory disclosure standards for the period.

ELI LILLY & Co Quarterly Report for Q2 Ended Jun 30, 1996

Summary

Key Highlights

Frequently Asked Questions